Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment

被引:0
|
作者
Kurosaki H. [1 ,2 ,5 ]
Oriuchi N. [3 ]
Okazaki A. [1 ]
Tamaki T. [1 ]
Uki A. [1 ]
Izuta M. [4 ]
Kojima R. [4 ]
Kato Y. [4 ]
Higuchi T. [3 ]
Maruno H. [1 ]
机构
[1] Department of Radiation Oncology and Nuclear Medicine, Toranomon Hospital
[2] Department of Radiology, Funabashi Municipal Medical Center
[3] Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine
[4] Department of Obstetrics and Gynecology, Toranomon Hospital
[5] Department of Radiology, Funabashi Municipal Medical Center, Funabashi, Chiba 273-8588
关键词
CA-125; FDG-PET; Ovarian carcinoma; Survival;
D O I
10.1007/BF03027426
中图分类号
学科分类号
摘要
Objective: To determine the prognostic value of FDG-PET after surgical resection in patients with ovarian carcinoma, we compared the results of FDG-PET and serum CA-125 level and prognosis of patients. Methods: Eighteen patients underwent a total of 32 FDG-PET examinations following surgery for ovarian carcinoma from October 2001 to December 2002 at our hospital (median follow-up period, 31 months). Age of the patients at the time of the initial FDG-PET examination ranged from 31 to 73 years (mean 52 years) and the period from surgery to the initial FDG-PET examination ranged from 5 to 109 months (mean 30 months). Serum CA-125 levels were determined on the occasion of each FDG-PET examination. Recurrent tumors were treated with surgery in 5 cases, radiotherapy in 2 cases, and chemotherapy in 9 cases. Results: The initial FDG-PET examinations revealed that 13 cases had positive and 5 cases had negative findings, which included 2 false positive cases. The survival rate for all patients at 1 year and 2 years after the initial examination was 82% and 63%, respectively. Two-year survival rates in patients with positive and negative FDG-PET findings were 51% and 83%, respectively, and the difference was not statistically significant (p = 0.19). Furthermore, 4 patients with normal CA-125 levels and 14 patients with elevated CA-125 levels showed 2-year survival rates of 100% and 51%, respectively, and they were not significantly different (p = 0.11). For all 32 examinations, the 2-year survival rates for patients with normal CA-125 levels (100%) were significantly higher (p = 0.025) than that for patients with elevated CA-125 levels (47%), however there was no significant difference (p = 0.20) between FDG-PET positive cases (53%) and negative cases (83%). Conclusion: The prognosis of patients with positive FDG-PET findings was less favorable than that of patients with negative findings. However, over the mean extended observation period of about 2.5 years, no significant difference in the prognosis of patients was observed between the two groups. The results of the present study indicate that elevated serum CA-125 levels may be more useful for evaluating the prognosis of ovarian cancer during the post-operative follow-up than FDG-PET findings.
引用
收藏
页码:171 / 174
页数:3
相关论文
共 50 条
  • [31] Clinical value of FDG-PET for recurrent renal cell carcinoma
    Nakatani, Koya
    Nakamoto, Yuji
    Suga, Tsuyoshi
    Kawai, Kanae
    Ishizu, Koichi
    Higashi, Tatsuya
    Saga, T.
    Togashi, Kaori
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [32] Value of delayed image of FDG-PET in the detection of hepatocellular carcinoma
    Lin, WY
    Wang, SJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S331 - S331
  • [33] Impact of FDG-PET on surgical management of melanoma patients
    Bastiaannet, E
    Meijer, S
    Oyen, W
    Hoekstra, O
    Wobbes, T
    Jager, P
    Hoekstra, H
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (02) : S94 - S94
  • [34] FDG-PET and hepatocellular carcinoma
    Toru Kashiwagi
    Journal of Gastroenterology, 2004, 39 : 1017 - 1018
  • [35] FDG-PET and hepatocellular carcinoma
    Kashiwagi, T
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (10) : 1017 - 1018
  • [36] FDG-PET in adrenocortical carcinoma
    Becherer, A
    Vierhapper, H
    Pötzi, C
    Karanikas, G
    Kurtaran, A
    Schmaljohann, J
    Staudenherz, A
    Dudczak, R
    Kletter, K
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (04) : 289 - 295
  • [37] Clinical and prognostic value of [18F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy
    Kunkel, M
    Helisch, A
    Reichert, TE
    Jeong, JH
    Buchholz, HG
    Benz, P
    Bartenstein, P
    Wagner, W
    Whiteside, TL
    ORAL ONCOLOGY, 2006, 42 (03) : 297 - 305
  • [38] Clinical value of FDG-PET in patients with autoimmune disorders
    Suga, Tsuyoshi
    Nakamoto, Yuji
    Higashi, Tatsuya
    Saga, Tsuneo
    Hara, Tadashi
    Togashi, Kaori
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [39] Value of FDG-PET for breast cancer patients.
    Budinger, TF
    Bunker, SR
    Hawkins, RA
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 287P - 287P
  • [40] Diagnostic value of FDG-PET in restaging of patients with osteosarcoma
    Szilvasi, I.
    Moravszki, M.
    Lengyel, Z.
    Szakall, S.
    Szendroi, M.
    Papai, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S275 - S276